NVCT — Nuvectis Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875558 ·
Last close
$21.52
Market Cap
$678.43M
52W High
$29.27
52W Low
$8.42
ADV30
496,133
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,260,000 | -6,050,000 | 25,398,000 | 25,130,000 | 11,178,000 |
| Dec 2025 | 0 | — | -7,617,000 | -7,314,000 | 31,709,000 | 31,634,000 | 13,296,000 |
| Sep 2025 | 0 | — | -7,794,000 | -7,462,000 | 35,587,000 | 35,442,000 | 11,577,000 |
| Jun 2025 | 0 | — | -6,595,000 | -6,334,000 | 27,007,000 | 26,793,000 | 10,135,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,009,000
Investing CF
$0
Financing CF
$29,110,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-99,687,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-27,574,000
Pretax Income TTM
$-26,442,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,574,000 | -26,442,000 | 31,709,000 | 13,296,000 | — | -16,009,000 |
| Dec 2024 | 0 | -19,847,000 | -19,000,000 | 18,607,000 | 8,894,000 | — | -12,247,000 |
| Dec 2023 | 0 | -22,897,000 | -22,260,000 | 19,185,000 | 6,984,000 | — | -15,954,000 |
| Dec 2022 | 0 | -19,234,000 | -19,085,000 | 20,405,000 | 6,186,000 | — | -13,559,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.96
Max Pain — expiry 2026-10-16
max pain strike: $15.00 · spot: $21.52 · call oi: 4,399 · put oi: 189Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EVO | Evotec SE | $678.79M | $1.91 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $681.06M | $36.81 | — |
| CLYM | Climb Bio, Inc. | $681.43M | $11.90 | — |
| STTK | Shattuck Labs, Inc. | $675.24M | $7.07 | — |
| CTMX | CytomX Therapeutics, Inc. | $674.88M | $3.10 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
2026-07-29 13:55 · Yahoo
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
2026-07-23 13:00 · Yahoo
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
2026-07-23 11:30 · Yahoo
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
2026-07-14 14:40 · Yahoo
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
2026-07-08 13:55 · Yahoo
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
2026-07-01 16:00 · Yahoo
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)
2026-06-30 12:36 · Yahoo
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
2026-06-30 02:30 · Yahoo
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
2026-06-29 20:01 · Yahoo
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
2026-06-26 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.